The research partnership between the University of Oxford and the four Berlin partners – Freie Universität Berlin, Humboldt-Universität zu Berlin, Technische Universität Berlin, and Charité – Universitätsmedizin Berlin – is picking up speed: all five…
Findings include stable disease and prolonged time on treatment vs. prior therapy in heavily pretreated metastatic pancreatic and colorectal cancer patients
The fatty acid propionate helps defend against the effects of high blood pressure, including atherosclerosis and heart tissue remodeling, a study on mice has found. Gut bacteria produce the substance – which calms the immune cells that drive up blood…
How does a normal cell turn into a deadly cancer? Seeking an answer to this question, and working alongside other international working groups, researchers from Charité – Universitätsmedizin Berlin examined the tumor genomes of nearly 300 prostate…
Implementing a project entitled ‘BrainPlay’, an interdisciplinary team of researchers will explore the way in which play affects the human brain. Researchers from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health (BIH),…
The CRISPR-Cas9 gene editing system has been generating excitement within the field of gene therapy, inspiring hopes of molecular tools capable of treating genetic diseases. By studying immune responses to CRISPR-Cas9 in humans, researchers from…
Over the last 13 years, Clariness has built a patient recruitment business covering 45 countries and 8 of
the top 10 pharmaceutical companies. “Clinical trials face increasing challenges in terms of cost and
timelines. Clariness strives to drive…
The German SME focuses on three technologies in the field of nanotechnology and biotechnology: tailored surface modification and encapsulation mainly by the Layer-by-Layer (LbL) technology platform; bead-based microsensors for bioanalysis; and…
Reference Number TO 32-00053
Myelo Therapeutics GmbH announced today that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to its orally applied new chemical entity Myelo001 for the treatment of Acute Radiation Syndrome (ARS).
